Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | LMNA | P02545 | 3/20 | 0.34 |
| ▸ | CASR | P41180 | 1/20 | 0.34 |
| ▸ | IGF1R | P08069 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.33 |
| ▸ | MITF | O75030 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13638260 | 0.91 | ALDH1A1 (0.35) | HTTSMN1; SMN2ALDH1A1LMNACASR | |
| SCHEMBL12670498 | 0.87 | SMN1; SMN2 (0.42) | HTTSMN1; SMN2ALDH1A1LMNACASR | |
| SCHEMBL1026823 | 0.79 | CYP3A4 (0.31) | HTTSMN1; SMN2LMNAKMT2AMAPT | |
| SCHEMBL3660804 | 0.79 | ALDH1A1 (0.35) | HTTALDH1A1LMNACASRKMT2A | |
| SCHEMBL13953572 | 0.78 | MTNR1A (0.33) | HTTALDH1A1LMNACASRKMT2A | |
| SCHEMBL13953360 | 0.74 | CACNA1G (0.33) | — | |
| SCHEMBL959435 | 0.74 | CACNA1G (0.33) | — | |
| SCHEMBL3638990 | 0.74 | ALOX5 (0.33) | — | |
| SCHEMBL3638992 | 0.74 | ALOX5 (0.33) | — | |
| SCHEMBL3638986 | 0.74 | ALOX5 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2274287-B1 | INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | VITAE PHARMACEUTICALS INC (US) | 2016-03-09 | — | — | EP | disclosed |
| EP-2274287-B1 | INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | VITAE PHARMACEUTICALS INC (US) | 2016-03-09 | — | — | EP | disclosed |
| US-20110105504-A1 | Inhibitors Of 11beta-Hydroxysteroid Dehydrogenase Type 1 | Vitae Pharmaceuticals ,Inc. | 2011-05-05 | — | — | US | disclosed |
| US-20110105504-A1 | Inhibitors Of 11beta-Hydroxysteroid Dehydrogenase Type 1 | Vitae Pharmaceuticals ,Inc. | 2011-05-05 | — | — | US | disclosed |
| WO-2009117109-A1 | INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 | VITAE PHARMACEUTICALS, INC. (US) | 2009-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105504-A1 | Inhibitors Of 11beta-Hydroxysteroid Dehydrogenase Type 1 | HSD11B1, HSD17B1, HSD11B2 | HTT 3011/4885SMN1; SMN2 1876/4885ALDH1A1 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.